You are here: Home: CACU 1 | 2007: Additional publications discussed during the program
ADDITIONAL PUBLICATIONS DISCUSSED DURING THE PROGRAM
Albain KS et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs paclitaxel
(T) as frontline therapy for metastatic breast cancer (MBC): First report of overall
survival. Proc ASCO 2004;Abstract 510.
Ali SM et al. Relationship of serum HER-2/neu and serum CA 15-3 in patients with
metastatic breast cancer. Clin Chem 2002;48(8):1314-20. Abstract
Burstein HJ et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes,
analysis of serum tumor markers as predictive factors, and cardiac surveillance
algorithm. J Clin Oncol 2003;21(15):2889-95. Abstract
Chan A et al; Navelbine Herceptin Project. Vinorelbine plus trastuzumab combination as
first-line therapy for HER 2-positive metastatic breast cancer patients: An international
phase II trial. Br J Cancer 2006;95(7):788-93. Abstract
Chlebowski RT et al. Dietary fat reduction and breast cancer outcome: Interim
efficacy results from the Women’s Intervention Nutrition Study. J Natl Cancer Inst
2006;98(24):1767-76. Abstract
Chlebowski RT et al. Influence of estrogen plus progestin on breast cancer and
mammography in healthy postmenopausal women: The Women’s Health Initiative
Randomized Trial. JAMA 2003;289(24):3243-53. Abstract
Clarke CA et al. Recent declines in hormone therapy utilization and breast cancer
incidence: Clinical and population-based evidence. J Clin Oncol 2006;24(33):e49-50. No
abstract available
Forbes JF et al. BCIRG 007: Randomized phase III trial of trastuzumab plus docetaxel
with or without carboplatin first line in HER2 positive metastatic breast cancer (MBC).
Proc ASCO 2006;Abstract LBA516.
Goss PE et al. Randomized trial of letrozole following tamoxifen as extended adjuvant
therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17.
J Natl Cancer Inst 2005;97(17):1262-71. Abstract
Hudis C et al. Five year follow-up of INT C9741: Dose-dense (DD) chemotherapy (CRx)
is safe and effective. San Antonio Breast Cancer Symposium 2005;Abstract 41.
Joensuu H et al. Amplification of erbB2 and erbB2 expression are superior to estrogen
receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: A
nationwide population-based study. Clin Cancer Res 2003;9(3):923-30. Abstract
Land SR et al. Patient-reported symptoms and quality of life during treatment with
tamoxifen or raloxifene for breast cancer prevention: The NSABP Study of Tamoxifen
and Raloxifene (STAR) P-2 trial. JAMA 2006;295(23):2742-51. Abstract
Lipton A et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole
versus tamoxifen. J Clin Oncol 2003;21(10):1967-72. Abstract
Lipton A et al. Elevated serum Her-2/neu level predicts decreased response to hormone
therapy in metastatic breast cancer. J Clin Oncol 2002;20(6):1467-72. Abstract
Miller KD et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial
coordinated by the Eastern Cooperative Oncology Group (E2100). San Antonio Breast
Cancer Symposium 2005;Abstract 3.
Mohsin SK et al. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers.
J Clin Oncol 2005;23(11):2460-8. Abstract
O’Shaughnessy J et al. Superior survival with capecitabine plus docetaxel combination
therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III
trial results. J Clin Oncol 2002;20(12):2812-23. Abstract
Pegram M et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18(13):2241- 51. Abstract
Press MF et al. Topoisomerase II-alpha gene amplification as a predictor of responsiveness
to anthracycline-containing chemotherapy in the Cancer International Research
Group 006 clinical trial of trastuzumab (Herceptin) in the adjuvant setting. San Antonio
Breast Cancer Symposium 2005;Abstract 1045.
Santen RJ et al. Adaptive hypersensitivity to estrogen: Mechanisms and clinical relevance
to aromatase inhibitor therapy in breast cancer treatment. J Steroid Biochem Mol Biol
2005;95(1-5):155-65. Abstract
Seidman AD et al. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-
hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of
metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and
randomized for T in HER2 normal MBC. Proc ASCO 2004;Abstract 512.
Slamon D et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide
followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed
by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab
(TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. San Antonio
Breast Cancer Symposium 2005;Abstract 1.
Spector NL et al. EGF103009, a phase II trial of lapatinib monotherapy in patients with
relapsed/refractory inflammatory breast cancer (IBC): Clinical activity and biologic
predictors of response. Proc ASCO 2006;Abstract 502.
Viale G et al. Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole
vs tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. San Antonio Breast Cancer Symposium 2005;Abstract 44.
Vogel VG et al; National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of
tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other
disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
JAMA 2006;295(23):2727-41. Abstract
Vogel CL et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment
of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20(3):719-26.
Abstract
|
